Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2020

Open Access 01-12-2020 | Cancer Immunotherapy | Review

Dexosomes as a cell-free vaccine for cancer immunotherapy

Authors: Sepideh Nikfarjam, Jafar Rezaie, Fatah Kashanchi, Reza Jafari

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2020

Login to get access

Abstract

Dendritic cells (DCs) secrete vast quantities of exosomes termed as dexosomes. Dexosomes are symmetric nanoscale heat-stable vesicles that consist of a lipid bilayer displaying a characteristic series of lipid and protein molecules. They include tetraspanins and all established proteins for presenting antigenic material such as the major histocompatibility complex class I/II (MHC I/II) and CD1a, b, c, d proteins and CD86 costimulatory molecule. Dexosomes contribute to antigen-specific cellular immune responses by incorporating the MHC proteins with antigen molecules and transferring the antigen-MHC complexes and other associated molecules to naïve DCs. A variety of ex vivo and in vivo studies demonstrated that antigen-loaded dexosomes were able to initiate potent antitumor immunity. Human dexosomes can be easily prepared using monocyte-derived DCs isolated by leukapheresis of peripheral blood and treated ex vivo by cytokines and other factors. The feasibility of implementing dexosomes as therapeutic antitumor vaccines has been verified in two phase I and one phase II clinical trials in malignant melanoma and non small cell lung carcinoma patients. These studies proved the safety of dexosome administration and showed that dexosome vaccines have the capacity to trigger both the adaptive (T lymphocytes) and the innate (natural killer cells) immune cell recalls. In the current review, we will focus on the perspective of utilizing dexosome vaccines in the context of cancer immunotherapy.
Literature
1.
Schlitzer A, McGovern N, Ginhoux F. Dendritic cells and monocyte-derived cells: Two complementary and integrated functional systems. Semin Cell Dev Biol. 2015;41:9–22.PubMedCrossRef
2.
Appay V, Douek DC, Price DA. CD8 + T cell efficacy in vaccination and disease. Nat Med. 2008;14(6):623–8.PubMedCrossRef
3.
Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, et al. ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4 < sup>+</sup > T Cells. Cancer Research. 2012;72(23):6130–41.PubMedCrossRef
4.
5.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.PubMedCrossRef
6.
Pitt JM, André F, Amigorena S, Soria JC, Eggermont A, Kroemer G, et al. Dendritic cell-derived exosomes for cancer therapy. J Clin Investig. 2016;126(4):1224–32.PubMedCrossRefPubMedCentral
7.
Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Indirect activation of naïve CD4 + T cells by dendritic cell-derived exosomes. Nat Immunol. 2002;3(12):1156–62.PubMedCrossRef
8.
Segura E. Review of Mouse and Human Dendritic Cell Subsets. Methods in molecular biology. (Clifton NJ). 2016;1423:3–15.
9.
10.
Guilliams M, Dutertre C-A, Scott Charlotte L, McGovern N, Sichien D, Chakarov S, et al. Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species. Immunity. 2016;45(3):669–84.PubMedPubMedCentralCrossRef
11.
Poulin LF, Reyal Y, Uronen-Hansson H, Schraml BU, Sancho D, Murphy KM, et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood. 2012;119(25):6052–62.PubMedCrossRef
12.
Cueto FJ, del Fresno C, Sancho D. DNGR-1, a Dendritic Cell-Specific Sensor of Tissue Damage That Dually Modulates Immunity and Inflammation. Frontiers in Immunology. 2020;10:3146. .PubMedPubMedCentralCrossRef
13.
Crozat K, Tamoutounour S, Vu Manh TP, Fossum E, Luche H, Ardouin L, et al. Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α + type. Journal of immunology (Baltimore, Md: 1950). 2011;187(9):4411-5.
14.
Mildner A, Jung S. Development and Function of Dendritic Cell Subsets. Immunity. 2014;40(5):642–56.PubMedCrossRef
15.
Facchetti F, Vermi W, Mason D, Colonna M. The plasmacytoid monocyte/interferon producing cells. Virchows Arch. 2003;443(6):703–17.PubMedCrossRef
16.
Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. Human Inflammatory Dendritic Cells Induce Th17 Cell Differentiation. Immunity. 2013;38(2):336–48.PubMedCrossRef
17.
Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356(6335):eaah4573.PubMedPubMedCentralCrossRef
18.
Tiberio L, Del Prete A, Schioppa T, Sozio F, Bosisio D, Sozzani S. Chemokine and chemotactic signals in dendritic cell migration. Cell Mol Immunol. 2018;15(4):346–52.PubMedPubMedCentralCrossRef
19.
Sozzani S, Vermi W, Del Prete A, Facchetti F. Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol. 2010;31(7):270–7.PubMedCrossRef
20.
21.
Bosisio D, Ronca R, Salvi V, Presta M, Sozzani S. Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. Curr Opin Immunol. 2018;53:180–6.PubMedCrossRef
22.
Sozzani S, Del Prete A, Bosisio D. Dendritic cell recruitment and activation in autoimmunity. J Autoimmun. 2017;85:126–40.PubMedCrossRef
23.
Vu Manh TP, Bertho N, Hosmalin A, Schwartz-Cornil I, Dalod M. Investigating Evolutionary Conservation of Dendritic Cell Subset Identity and Functions. Front Immunol. 2015;6:260.PubMedPubMedCentral
24.
Cancel J-C, Crozat K, Dalod M, Mattiuz R. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? Frontiers in immunology. 2019;10:9-.
25.
26.
Theisen DJ, Davidson JT, Briseño CG, Gargaro M, Lauron EJ, Wang Q, et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science. 2018;362(6415):694–9.PubMedPubMedCentralCrossRef
27.
Alloatti A, Rookhuizen DC, Joannas L, Carpier J-M, Iborra S, Magalhaes JG, et al. Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. J Exp Med. 2017;214(8):2231–41.PubMedPubMedCentralCrossRef
28.
Theisen DJ, Ferris ST, Briseño CG, Kretzer N, Iwata A, Murphy KM, et al. Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation. Cancer immunology research. 2019;7(1):29–39.PubMed
29.
Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. 2016;30(2):324–36.PubMedPubMedCentralCrossRef
30.
31.
Matsuo K, Kitahata K, Kawabata F, Kamei M, Hara Y, Takamura S, et al. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8(+) T Cells. Front Immunol. 2018;9:2775.PubMedPubMedCentralCrossRef
32.
Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017;31(5):711 – 23.e4.PubMedPubMedCentralCrossRef
33.
Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458.PubMedCrossRef
34.
Kastenmüller W, Brandes M, Wang Z, Herz J, Egen JG, Germain RN. Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8 + T cell responses in the lymph node. Immunity. 2013;38(3):502–13.PubMedPubMedCentralCrossRef
35.
Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Martínez-Cano S, et al. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8 + T cells. Nat Commun. 2017;8(1):16073.PubMedPubMedCentralCrossRef
36.
Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638–52.PubMedPubMedCentralCrossRef
37.
Mittal D, Vijayan D, Putz EM, Aguilera AR, Markey KA, Straube J, et al. Interleukin-12 from CD103 < sup>+</sup > Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis. Cancer immunology research. 2017;5(12):1098–108.PubMedCrossRef
38.
Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho Christine MT, Pryer N, et al. Macrophage IL-10 Blocks CD8 < sup>+</sup > T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. Cancer Cell. 2014;26(5):623–37.PubMedPubMedCentralCrossRef
39.
Greyer M, Whitney Paul G, Stock Angus T, Davey Gayle M, Tebartz C, Bachem A, et al. T Cell Help Amplifies Innate Signals in CD8 < sup>+</sup > DCs for Optimal CD8 < sup>+</sup > T Cell Priming. Cell Reports. 2016;14(3):586–97.PubMedCrossRef
40.
Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018;172(5):1022–37.e14.PubMedPubMedCentralCrossRef
41.
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24(8):1178–91.PubMedPubMedCentralCrossRef
42.
Hor Jyh L, Whitney Paul G, Zaid A, Brooks Andrew G, Heath William R, Mueller Scott N. Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4 < sup>+</sup > and CD8 < sup>+</sup > T Cell Activation to Localized Viral Infection. Immunity. 2015;43(3):554–65.PubMedCrossRef
43.
Brewitz A, Eickhoff S, Dähling S, Quast T, Bedoui S, Kroczek RA, et al. CD8 < sup>+</sup > T Cells Orchestrate pDC-XCR1 < sup>+</sup > Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming. Immunity. 2017;46(2):205–19.PubMedPubMedCentralCrossRef
44.
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989–2003.PubMedPubMedCentralCrossRef
45.
Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8 + T cell responses through CD8α + dendritic cells. J Exp Med. 2011;208(10):2005–16.PubMedPubMedCentralCrossRef
46.
Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun. 2016;7(1):13720.PubMedPubMedCentralCrossRef
47.
Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer immunology research. 2014;2(2):91–8.PubMedCrossRef
48.
Kennedy R, Celis E. Multiple roles for CD4 + T cells in anti-tumor immune responses. Immunol Rev. 2008;222:129–44.PubMedCrossRef
49.
Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637–50.PubMedPubMedCentralCrossRef
50.
Qin Z, Blankenstein T. CD4 T Cell;Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFN. Receptor Expression by Nonhematopoietic Cells Immunity. 2000;12(6):677–86. .PubMed
51.
Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4 + T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635–47.PubMedCrossRef
52.
Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and Activation of CD103 < sup>+</sup > Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016;44(4):924–38.PubMedPubMedCentralCrossRef
53.
54.
Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4 < sup>+</sup > T Cell Immunity. Cell. 2019;177(3):556 – 71.e16.PubMedPubMedCentralCrossRef
55.
Leal Rojas IM, Mok W-H, Pearson FE, Minoda Y, Kenna TJ, Barnard RT, et al. Human Blood CD1c + Dendritic Cells Promote Th1 and Th17 Effector Function in Memory CD4 + T Cells. Frontiers in Immunology. 2017;8(971).
56.
Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015;50(7):924–30.PubMedPubMedCentralCrossRef
57.
Pinzon-Charry A, Ho CSK, Maxwell T, McGuckin MA, Schmidt C, Furnival C, et al. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer. 2007;97(9):1251–9.PubMedPubMedCentralCrossRef
58.
Michea P, Noël F, Zakine E, Czerwinska U, Sirven P, Abouzid O, et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat Immunol. 2018;19(8):885–97.PubMedCrossRef
59.
Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, et al. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. Immunity. 2019;50(5):1317–34.e10.PubMedPubMedCentralCrossRef
60.
Koucký V, Bouček J, Fialová A. Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review. Cancers. 2019;11(4).
61.
Wu J, Li S, Yang Y, Zhu S, Zhang M, Qiao Y, et al. TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo. Oncotarget. 2016;8(7).
62.
Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Investig. 2012;122(2):575–85.PubMedCrossRefPubMedCentral
63.
Riboldi E, Daniele R, Cassatella MA, Sozzani S, Bosisio D. Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. Immunobiology. 2009;214(9):868–76.PubMedCrossRef
64.
Salvi V, Vermi W, Cavani A, Lonardi S, Carbone T, Facchetti F, et al. IL-21 May Promote Granzyme B-Dependent NK/Plasmacytoid Dendritic Cell;Functional Interaction in Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology. 2017;137(7):1493–500. .PubMedCrossRef
65.
Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Investig. 2008;118(3):1165–75.PubMedPubMedCentral
66.
Poropatich K, Dominguez D, Chan WC, Andrade J, Zha Y, Wray B, et al. OX40 + plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity. J Clin Investig. 2020;130(7):3528–42.PubMedCrossRefPubMedCentral
67.
Kuhn S, Yang J, Ronchese F. Monocyte-Derived Dendritic Cells Are Essential for CD8(+) T Cell Activation and Antitumor Responses After Local Immunotherapy. Front Immunol. 2015;6:584.PubMedPubMedCentralCrossRef
68.
Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729–41.CrossRefPubMed
69.
Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016;44(2):343–54.PubMedPubMedCentralCrossRef
70.
Diao J, Gu H, Tang M, Zhao J, Cattral MS. Tumor Dendritic Cells (DCs) Derived from Precursors of Conventional DCs Are Dispensable for Intratumor CTL Responses. Journal of immunology (Baltimore, Md: 1950). 2018;201(4):1306-14.
71.
Van Niel G, d’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nature reviews Molecular cell biology. 2018;19(4):213.PubMedCrossRef
72.
Minciacchi VR, Freeman MR, Di Vizio D. Extracellular Vesicles in Cancer: Exosomes, Microvesicles and the Emerging Role of Large Oncosomes. Semin Cell Dev Biol. 2015;40:41–51.PubMedPubMedCentralCrossRef
73.
Février B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol. 2004;16(4):415–21.PubMedCrossRef
74.
Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18(1):75.PubMedPubMedCentralCrossRef
75.
Jabbari N, Karimipour M, Khaksar M, Akbariazar E, Heidarzadeh M, Mojarad B, et al. Tumor-derived extracellular vesicles: insights into bystander effects of exosomes after irradiation. Lasers in medical science. 2019:1–15.
76.
77.
Zimmermann P, Zhang Z, Degeest G, Mortier E, Leenaerts I, Coomans C, et al. Syndecan recycling is controlled by syntenin-PIP2 interaction and Arf6 (vol 9, pg 377, 2005). Developmental cell. 2005;9(5):721-.
78.
Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernández-Delgado I, Torralba D, Moreno-Gonzalo O, et al. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. Nat Commun. 2016;7(1):13588.PubMedPubMedCentralCrossRef
79.
Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. Journal of cell science. 2013;126(24):5553–65.PubMedCrossRef
80.
Yeates EFA, Tesco G. The endosome-associated deubiquitinating enzyme USP8 regulates BACE1 enzyme ubiquitination and degradation. J Biol Chem. 2016;291(30):15753–66.PubMedPubMedCentralCrossRef
81.
Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. Syndecan–syntenin–ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012;14(7):677–85.PubMedCrossRef
82.
Stuffers S, Sem Wegner C, Stenmark H, Brech A. Multivesicular Endosome Biogenesis in the Absence of ESCRTs. Traffic. 2009;10(7):925–37.PubMedCrossRef
83.
Goñi FM, Alonso A. Effects of ceramide and other simple sphingolipids on membrane lateral structure. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2009;1788(1):169–77.CrossRef
84.
Odintsova E, van Niel G, Conjeaud H, Raposo G, Iwamoto R, Mekada E, et al. Metastasis Suppressor Tetraspanin CD82/KAI1 Regulates Ubiquitylation of Epidermal Growth Factor Receptor. J Biol Chem. 2013;288(36):26323–34.PubMedPubMedCentralCrossRef
85.
Chairoungdua A, Smith DL, Pochard P, Hull M, Caplan MJ. Exosome release of β-catenin: a novel mechanism that antagonizes Wnt signaling. J Cell Biol. 2010;190(6):1079–91.PubMedPubMedCentralCrossRef
86.
Zhu H, Guariglia S, Yu RYL, Li W, Brancho D, Peinado H, et al. Mutation of SIMPLE in Charcot–Marie–Tooth 1C alters production of exosomes. Mol Biol Cell. 2013;24(11):1619–37.PubMedPubMedCentralCrossRef
87.
Hoshino D, Kirkbride Kellye C, Costello K, Clark Emily S, Sinha S, Grega-Larson N, et al. Exosome Secretion Is Enhanced by Invadopodia and Drives Invasive Behavior. Cell Reports. 2013;5(5):1159–68.PubMedCrossRef
88.
Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12(1):19–30.PubMedCrossRef
89.
90.
Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature reviews immunology. 2002;2(8):569–79.PubMedCrossRef
91.
Segura E, Nicco C, Lombard B, Véron P, Raposo G, Batteux F, et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood. 2005;106(1):216–23.PubMedCrossRef
92.
Diamond MS, Staunton DE, de Fougerolles AR, Stacker SA, Garcia-Aguilar J, Hibbs ML, et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol. 1990;111(6 Pt 2):3129–39.PubMedCrossRef
93.
Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987;51(5):813–9.PubMedCrossRef
94.
Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001;166(12):7309–18.PubMedCrossRef
95.
Clayton A, Harris CL, Court J, Mason MD, Morgan BP. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur J Immunol. 2003;33(2):522–31.PubMedCrossRef
96.
Katzmann DJ, Odorizzi G, Emr SD. Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol. 2002;3(12):893–905.PubMedCrossRef
97.
Théry C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular Characterization of Dendritic Cell-Derived Exosomes: Selective Accumulation of the Heat Shock Protein Hsc73. J Cell Biol. 1999;147(3):599–610.PubMedPubMedCentralCrossRef
98.
Véron P, Segura E, Sugano G, Amigorena S, Théry C. Accumulation of MFG-E8/lactadherin on exosomes from immature dendritic cells. Blood Cells Molecules Diseases. 2005;35(2):81–8.CrossRefPubMed
99.
Tamura Y, Torigoe T, Kukita K, Saito K, Okuya K, Kutomi G, et al. Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity. Immunotherapy. 2012;4(8):841–52.PubMedCrossRef
100.
Montecalvo A, Larregina AT, Shufesky WJ, Beer Stolz D, Sullivan MLG, Karlsson JM, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012;119(3):756–66.PubMedPubMedCentralCrossRef
101.
Laulagnier K, Motta C, Hamdi S, Roy S, Fauvelle F, Pageaux J-F, et al. Mast cell-and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J. 2004;380(1):161–71.PubMedPubMedCentralCrossRef
102.
Laulagnier K, Grand D, Dujardin A, Hamdi S, Vincent-Schneider H, Lankar D, et al. PLD2 is enriched on exosomes and its activity is correlated to the release of exosomes. FEBS Lett. 2004;572(1–3):11–4.PubMedCrossRef
103.
Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol. 1985;101(3):942–8.PubMedCrossRef
104.
Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζ complex. J Immunol. 2002;168(7):3235–41.PubMedCrossRef
105.
Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C, Desaymard C. Accumulation of Major Histocompatibility Complex Class II Molecules in Mast Cell Secretory Granules and Their Release upon Degranulation. Mol Biol Cell. 1997;8(12):2631–45.PubMedPubMedCentralCrossRef
106.
Arita S, Baba E, Shibata Y, Niiro H, Shimoda S, Isobe T, et al. B cell activation regulates exosomal HLA production. Eur J Immunol. 2008;38(5):1423–34.PubMedCrossRef
107.
Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nature medicine. 1998;4(5):594–600.PubMedCrossRef
108.
Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood. 2007;110(9):3234–44.PubMedPubMedCentralCrossRef
109.
Buschow SI, Nolte-‘t Hoen EN, Van Niel G, Pols MS, Ten Broeke T, Lauwen M, et al. MHC II in dendritic cells is targeted to lysosomes or T cell‐induced exosomes via distinct multivesicular body pathways. Traffic. 2009;10(10):1528–42.PubMedCrossRef
110.
Nolte-‘t Hoen ENM, van der Vlist EJ, de Boer-Brouwer M, Arkesteijn GJA, Stoorvogel W, Wauben MHM. Dynamics of dendritic cell-derived vesicles: high-resolution flow cytometric analysis of extracellular vesicle quantity and quality. J Leukoc Biol. 2013;93(3):395–402.PubMedCrossRef
111.
Viaud S, Ploix S, Lapierre V, Théry C, Commere P-H, Tramalloni D, et al. Updated Technology to Produce Highly Immunogenic Dendritic Cell-derived Exosomes of Clinical Grade: A Critical Role of Interferon-γ. J Immunother. 2011;34(1):65–75.PubMedCrossRef
112.
Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine JC, et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differentiation. 2008;15(11):1723–33.PubMedCrossRef
113.
Bianco NR, Kim SH, Ruffner MA, Robbins PD. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis rheumatism. 2009;60(2):380–9.PubMedCrossRef
114.
Johansson SM, Admyre C, Scheynius A, Gabrielsson S. Different types of in vitro generated human monocyte-derived dendritic cells release exosomes with distinct phenotypes. Immunology. 2008;123(4):491–9.PubMedCrossRef
115.
Kim S-H, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol. 2005;174(10):6440–8.PubMedCrossRef
116.
Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, et al. Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population for Efficient CTL Priming. Immunity. 2006;25(1):153–62.PubMedCrossRef
117.
Vincent-Schneider H, Stumptner‐Cuvelette P, Lankar D, Pain S, Raposo G, Benaroch P, et al. Exosomes bearing HLA‐DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol. 2002;14(7):713–22.PubMedCrossRef
118.
André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 2004;172(4):2126–36.PubMedCrossRef
119.
120.
Montecalvo A, Shufesky WJ, Beer Stolz D, Sullivan MG, Wang Z, Divito SJ, et al. Exosomes As a Short-Range Mechanism to Spread Alloantigen between Dendritic Cells during T Cell Allorecognition. J Immunol. 2008;180(5):3081–90.PubMedCrossRef
121.
Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, Papworth GD, et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood. 2004;104(10):3257–66.CrossRefPubMed
122.
123.
Mallegol J, Van Niel G, Lebreton C, Lepelletier Y, Candalh C, Dugave C, et al. T84-Intestinal Epithelial Exosomes Bear MHC Class II/Peptide Complexes Potentiating Antigen Presentation by Dendritic Cells. Gastroenterology. 2007;132(5):1866–76.PubMedCrossRef
124.
Nakayama M. Antigen Presentation by MHC-Dressed Cells. Front Immunol. 2014;5:672.PubMed
125.
Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Indirect activation of naïve CD4 + T cells by dendritic cell–derived exosomes. Nature immunology. 2002;3(12):1156–62.PubMedCrossRef
126.
127.
Romagnoli GG, Zelante BB, Toniolo PA, Migliori IK, Barbuto JAM. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Frontiers in immunology. 2015;5:692.PubMedPubMedCentralCrossRef
128.
Chen Daniel S, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013;39(1):1–10.PubMedCrossRef
129.
Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology. 2012;1(7):1074–83.PubMedPubMedCentralCrossRef
130.
Wang J, Wang Z, Mo Y, Zeng Z, Wei P, Li T. Effect of hyperthermic CO(2)-treated dendritic cell-derived exosomes on the human gastric cancer AGS cell line. Oncology letters. 2015;10(1):71–6.PubMedPubMedCentralCrossRef
131.
Guo F, Chang CK, Fan HH, Nie XX, Ren YN, Liu YY, et al. Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid. J Int Med Res. 2008;36(6):1342–53.PubMedCrossRef
132.
Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, et al. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PloS one. 2008;3(10).
133.
Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Rα. PloS one. 2009;4(3).
134.
Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One. 2009;4(3):e4942.PubMedPubMedCentralCrossRef
135.
Sobo-Vujanovic A, Munich S, Vujanovic NL. Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells. Cell Immunol. 2014;289(1–2):119–27.PubMedPubMedCentralCrossRef
136.
Luketic L, Delanghe J, Sobol PT, Yang P, Frotten E, Mossman KL, et al. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol. 2007;179(8):5024–32.PubMedCrossRef
137.
Hsu D-H, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, et al. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. Journal of immunotherapy. 2003;26(5):440–50.PubMedCrossRef
138.
Admyre C, Johansson SM, Paulie S, Gabrielsson S. Direct exosome stimulation of peripheral humanT cells detected by ELISPOT. Eur J Immunol. 2006;36(7):1772–81.PubMedCrossRef
139.
Lawand M, Abramova A, Manceau V, Springer S, van Endert P. TAP-Dependent and -Independent Peptide Import into Dendritic Cell Phagosomes. Journal of immunology (Baltimore, Md: 1950). 2016;197(9):3454-63.
140.
Palmowski MJ, Gileadi U, Salio M, Gallimore A, Millrain M, James E, et al. Role of immunoproteasomes in cross-presentation. Journal of immunology (Baltimore, Md: 1950). 2006;177(2):983 – 90.
141.
Ackerman AL, Giodini A, Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity. 2006;25(4):607–17.PubMedCrossRef
142.
Näslund TI, Gehrmann U, Qazi KR, Karlsson MC, Gabrielsson S. Dendritic cell–derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol. 2013;190(6):2712–9.PubMedCrossRef
143.
Hao S, Bai O, Li F, Yuan J, Laferte S, Xiang J. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology. 2007;120(1):90–102.PubMedPubMedCentralCrossRef
144.
Hao S, Bai O, Yuan J, Qureshi M, Xiang J. Dendritic cell-derived exosomes stimulate stronger CD8 + CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol. 2006;3(3):205–11.PubMed
145.
Gehrmann U, Hiltbrunner S, Georgoudaki A-M, Karlsson MC, Näslund TI, Gabrielsson S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer research. 2013;73(13):3865–76.PubMedCrossRef
146.
Guan S, Li Q, Liu P, Xuan X, Du Y. Umbilical cord blood-derived dendritic cells loaded with BGC823 tumor antigens and DC-derived exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumor immunity in vitro and in vivo. Central-European journal of immunology. 2014;39(2):142–51.PubMedPubMedCentralCrossRef
147.
Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. Journal of immunology (Baltimore, Md: 1950). 2007;179(4):2242-9.
148.
Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Molecular therapy: the journal of the American Society of Gene Therapy. 2006;13(2):289–300.CrossRef
149.
Peche H, Renaudin K, Beriou G, Merieau E, Amigorena S, Cuturi M. Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC‐mismatched rat cardiac allograft model. American journal of transplantation. 2006;6(7):1541–50.PubMedCrossRef
150.
Liu Y-Y, Fan H-H, Ren Y-N, Yang J, Nie X-X, Zhao L-H, et al. [Immune tolerance induced by exosomes derived from regulatory dendritic cells of mice]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16(2):406–10.PubMed
151.
Bianco NR, Kim SH, Ruffner MA, Robbins PD. Therapeutic effect of exosomes from indoleamine 2, 3-dioxygenase–positive dendritic cells in collagen‐induced arthritis and delayed‐type hypersensitivity disease models. Arthritis Rheumatism: Official Journal of the American College of Rheumatology. 2009;60(2):380–9.CrossRef
152.
Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. Journal of hepatology. 2017;67(4):739–48.PubMedCrossRef
153.
154.
Damo M, Wilson DS, Simeoni E, Hubbell JA. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci Rep. 2015;5(1):17622.PubMedPubMedCentralCrossRef
155.
Qazi KR, Gehrmann U, Domange Jordö E, Karlsson MC, Gabrielsson S. Antigen-loaded exosomes alone induce Th1-type memory through a B cell–dependent mechanism. Blood. The Journal of the American Society of Hematology. 2009;113(12):2673–83.
156.
Segura E, Guérin C, Hogg N, Amigorena S, Théry C. CD8 + dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes in vivo. J Immunol. 2007;179(3):1489–96.PubMedCrossRef
157.
Näslund TI, Gehrmann U, Qazi KR, Karlsson MC, Gabrielsson S. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. Journal of immunology (Baltimore, Md: 1950). 2013;190(6):2712-9.
158.
Quah BJ, O’neill HC. Mycoplasma contaminants present in exosome preparations induce polyclonal B cell responses. J Leukoc Biol. 2007;82(5):1070–82.PubMedCrossRef
159.
Pêche H, Heslan M, Usal C, Amigorena S, Cuturi MC. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection1. Transplantation. 2003;76(10):1503–10.PubMedCrossRef
160.
Colino J, Snapper CM. Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen. J Immunol. 2006;177(6):3757–62.PubMedCrossRef
161.
Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. Journal of Translational Medicine. 2005;3(1):9.PubMedPubMedCentralCrossRef
162.
Escudier B, Dorval T, Chaput N, André F, Caby M-P, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. Journal of translational medicine. 2005;3(1):10-.PubMedPubMedCentralCrossRef
163.
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):e1071008.PubMedCrossRef
164.
Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, et al. Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function. PLOS ONE. 2008;3(10):e3377.PubMedPubMedCentralCrossRef
165.
Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners Katrin S, Hansen HP, et al. Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells. Immunity. 2007;27(6):965–74.
166.
Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, et al. Dendritic Cell-Derived Exosomes for Cancer Immunotherapy: What’s Next? Can Res. 2010;70(4):1281–5.CrossRef
167.
Taieb J, Chaput N, Schartz N, Roux S, Novault S, Ménard C, et al. Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. J Immunol. 2006;176(5):2722–9.PubMedCrossRef
168.
Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, et al. Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. Can Res. 2011;71(3):661–5.CrossRef
169.
Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. Science. 2013;342(6161):971–6.PubMedPubMedCentralCrossRef
170.
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641–8.PubMedCrossRef
171.
Kämper N, Franken S, Temme S, Koch S, Bieber T, Koch N. 7-Interferon-regulated chaperone governs human lymphocyte antigen class II expression. FASEB J. 2012;26(1):104–16.PubMedCrossRef
172.
173.
Saxena M, Balan S, Roudko V, Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. Nature biomedical engineering. 2018;2(6):341–6.PubMedPubMedCentralCrossRef
174.
Parmiani G, Pilla L, Castelli C, Rivoltini L. Vaccination of patients with solid tumours. Ann Oncol. 2003;14(6):817–24.PubMedCrossRef
175.
Briseño CG, Haldar M, Kretzer NM, Wu X, Theisen DJ, Wumesh K, et al. Distinct transcriptional programs control cross-priming in classical and monocyte-derived dendritic cells. Cell reports. 2016;15(11):2462–74.PubMedCrossRef
176.
Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, et al. Human XCR1 + dendritic cells derived in vitro from CD34 + progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells. J Immunol. 2014;193(4):1622–35.PubMedPubMedCentralCrossRef
177.
De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63(1):12–7.PubMed
178.
Shinde P, Fernandes S, Melinkeri S, Kale V, Limaye L. Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy. Sci Rep. 2018;8(1):5705.PubMedPubMedCentralCrossRef
179.
Breton G, Lee J, Zhou YJ, Schreiber JJ, Keler T, Puhr S, et al. Circulating precursors of human CD1c + and CD141 + dendritic cells. J Exp Med. 2015;212(3):401–13.PubMedPubMedCentralCrossRef
180.
Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73(3):1063–75.PubMedCrossRef
181.
Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, et al. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016;22(9):2155–66.CrossRef
182.
Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D’Rozario R, et al. A phase I clinical trial of CD1c (BDCA-1) + dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. Journal of immunotherapy (Hagerstown, Md: 1997). 2015;38(2):71–6.
183.
Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J immunother Cancer. 2019;7(1):109.PubMedPubMedCentralCrossRef
184.
Kirkling ME, Cytlak U, Lau CM, Lewis KL, Resteu A, Khodadadi-Jamayran A, et al. Notch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic Cells. Cell Rep. 2018;23(12):3658–72.e6.PubMedPubMedCentralCrossRef
185.
Balan S, Arnold-Schrauf C, Abbas A, Couespel N, Savoret J, Imperatore F, et al. Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity. Cell Rep. 2018;24(7):1902. -15.e6..PubMedPubMedCentralCrossRef
186.
Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes AM, Palma LG, et al. Direct reprogramming of fibroblasts into antigen-presenting dendritic cells. Science immunology. 2018;3:30. .CrossRef
187.
Wculek SK, Amores-Iniesta J, Conde-Garrosa R, Khouili SC, Melero I, Sancho D. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. J immunother Cancer. 2019;7(1):100.PubMedPubMedCentralCrossRef
188.
Pearson FE, Chang K, Minoda Y, Rojas IML, Haigh OL, Daraj G, et al. Activation of human CD141(+) and CD1c(+) dendritic cells in vivo with combined TLR3 and TLR7/8 ligation. Immunol Cell Biol. 2018;96(4):390–400.PubMedCrossRef
189.
Roselli E, Araya P, Núñez NG, Gatti G, Graziano F, Sedlik C, et al. TLR3 Activation of Intratumoral CD103(+) Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity. Front Immunol. 2019;10:503.PubMedPubMedCentralCrossRef
190.
Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018;10:436. .CrossRef
191.
Squadrito ML, Cianciaruso C, Hansen SK, De Palma M. EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat Methods. 2018;15(3):183–6.PubMedPubMedCentralCrossRef
192.
Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270–4.PubMedPubMedCentralCrossRef
193.
Hobo W, Maas F, Adisty N, de Witte T, Schaap N, van der Voort R, et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen–specific CD8 + T cells. Blood. 2010;116(22):4501–11.PubMedCrossRef
194.
195.
Cueto FJ, Del Fresno C, Sancho D. DNGR-1, a Dendritic Cell-Specific Sensor of Tissue Damage That Dually Modulates Immunity and Inflammation. Front Immunol. 2019;10:3146.PubMedCrossRef
196.
Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, et al. Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. Cancer Res. 2018;78(2):463–74.PubMedCrossRef
197.
Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, et al. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8(+) T-cell Infiltration. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017;23(16):4556–68.CrossRef
198.
Terhorst D, Fossum E, Baranska A, Tamoutounour S, Malosse C, Garbani M, et al. Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1 + dendritic cells induces potent antitumoral responses. J Immunol (Baltimore, Md: 1950). 2015;194(12):5895–902.
199.
Hartung E, Becker M, Bachem A, Reeg N, Jäkel A, Hutloff A, et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. Journal of immunology (Baltimore, Md: 1950). 2015;194(3):1069-79.
200.
Escudier B, Dorval T, Chaput N, André F, Caby M-P, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3(1):10.PubMedPubMedCentralCrossRef
201.
Germain RN, Bajénoff M, Castellino F, Chieppa M, Egen JG, Huang AYC, et al. Making friends in out-of-the-way places: how cells of the immune system get together and how they conduct their business as revealed by intravital imaging. Immunol Rev. 2008;221(1):163–81.PubMedCrossRef
202.
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, et al. Trial Watch OncoImmunology. 2014;3(3):e27878.PubMedCrossRef
203.
Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, et al. IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma. Can Res. 2014;74(21):6060–70.CrossRef
Metadata
Title
Dexosomes as a cell-free vaccine for cancer immunotherapy
Authors
Sepideh Nikfarjam
Jafar Rezaie
Fatah Kashanchi
Reza Jafari
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2020
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-020-01781-x

Other articles of this Issue 1/2020

Journal of Experimental & Clinical Cancer Research 1/2020 Go to the issue

Research

KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma

Research

Long noncoding RNA RP11-757G1.5 sponges miR-139-5p and upregulates YAP1 thereby promoting the proliferation and liver, spleen metastasis of colorectal cancer

Research

Different p53 genotypes regulating different phosphorylation sites and subcellular location of CDC25C associated with the formation of polyploid giant cancer cells

Correction

Correction to: IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2

Meeting Report

From single gene analysis to single cell profiling: a new era for precision medicine

Research

M2 macrophage-derived extracellular vesicles promote gastric cancer progression via a microRNA-130b-3p/MLL3/GRHL2 signaling cascade
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits